Loading…
Saffron USA LLC was cited for marketing five herbal tea and botanical blend products (Allergy Blend, Chamomile Tea Petals, Diabetic Support Blend, Orange Blast Tea, and Saffron Loose Tea) as unapproved drugs through disease claims on their website. The company violated federal law by making therapeutic claims including treatment of allergies, asthma, diabetes, cancer, inflammation, and high blood pressure without FDA approval, which classified these products as drugs under the Federal Food, Drug, and Cosmetic Act. The violations were identified during an FDA review of the company's website in September 2022, where health benefit claims established the products' intended use for curing, mitigating, treating, or preventing disease.